Semaglutide Peptide Treatment Guide

Semaglutide is a GLP-1 receptor agonist studied primarily for type 2 diabetes and chronic weight management. This page explains what it is and how clinician-supervised treatment through ElliotMeds works. It is educational and not medical advice.

Last updated: July 2, 2026

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The only FDA-approved semaglutide products are Wegovy (chronic weight management and cardiovascular-risk reduction in certain adults), Ozempic (type 2 diabetes and associated risk reduction), and Rybelsus (oral semaglutide for type 2 diabetes). Compounded semaglutide is not FDA-approved and is not the same as any of these branded products — it does not go through the FDA review for safety, effectiveness, and quality that approved drugs undergo. Since the FDA declared the semaglutide shortage resolved (February 2025), compounded semaglutide may generally be prepared only for an individual patient when a licensed clinician documents a specific clinical reason the approved product is unsuitable — not for cost or convenience.

How It Works

Semaglutide activates GLP-1 receptors involved in appetite and satiety signaling, glucose-dependent insulin secretion, glucagon regulation, and the rate of gastric emptying. Research and FDA labeling indicate this signaling can reduce appetite and food intake when combined with nutrition, activity, and clinical monitoring. It is not a guaranteed weight-loss outcome, and individual results vary.

What It’s Studied For

FDA-approved semaglutide products have been studied in large trial programs — STEP (weight management), SUSTAIN (type 2 diabetes), and SELECT (cardiovascular outcomes) — and carry formal labeling for those uses. Compounded semaglutide has not been separately studied or FDA-reviewed; any use is determined case-by-case by a licensed clinician.

What to Expect

Approved-label semaglutide is typically started at a low dose and increased gradually over weeks to months, in part to reduce gastrointestinal side effects; effects on appetite and weight generally build over time rather than immediately. Timelines vary by person, and treatment is never guaranteed. Studies and clinical experience suggest weight regain is common if treatment stops and lifestyle changes aren't maintained. This program does not promise any specific result or timeline.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Commonly reported: nausea, vomiting, diarrhea, constipation, and abdominal pain.
• More serious reported risks include pancreatitis, gallbladder problems, acute kidney injury related to dehydration, and hypoglycemia when combined with insulin or sulfonylureas.
• FDA-approved GLP-1 labeling carries a boxed warning based on thyroid C-cell tumors seen in rodent studies; human relevance is not established, but the labels contraindicate use with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
• No peptide is 'safe' in the absolute — risks are weighed against potential benefit by your clinician.

Who Is Not a Candidate

Personal or family history of MTC or MEN2; prior serious hypersensitivity to semaglutide; type 1 diabetes or diabetic ketoacidosis. It is not recommended in pregnancy and is generally stopped before a planned pregnancy; disclose pregnancy, breastfeeding, kidney disease, gastrointestinal disease, gallbladder or pancreatitis history, and all medications during intake.

How It Compares

Both semaglutide and tirzepatide are injectable incretin-based medications used in weight management and diabetes contexts. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on two receptors (GIP and GLP-1). They differ in mechanism and side-effect profile; neither is presented here as superior, and a clinician determines which, if either, is appropriate.

Frequently Asked Questions

References

• FDA Prescribing Information — Wegovy, Ozempic, Rybelsus
• NEJM STEP, SUSTAIN, and SELECT trial publications
• MedlinePlus — semaglutide
• FDA statements on compounded semaglutide and dosing-error reports